Invasive Pneumococcal Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | MSD K.K, Pfizer, SK Bioscience/ Sanofi, Walvax Biotechnology Co., Ltd., GlaxoSmithKline

DelveInsight's "Invasive Pneumococcal Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Invasive Pneumococcal Disease, historical and forecasted epidemiology as well as the Invasive Pneumococcal Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Invasive Pneumococcal Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Invasive Pneumococcal Disease Market Forecast
https://www.delveinsight.com/sample-request/invasive-pneumococcal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Invasive Pneumococcal Disease Market Report:
• The Invasive Pneumococcal Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In June 2024, Merck's CAPVAXIVE (V116) has become the first Pneumococcal 21-valent Conjugate Vaccine approved for the prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in adults. This powerful vaccine incorporates eight unique serotypes that are not included in any other approved pneumococcal vaccines, which represent approximately 27% of IPD cases in adults aged 50 and older and around 30% in those aged 65 and above, according to CDC data. While the precise mechanism of the vaccine's action remains unclear, CAPVAXIVE is designed to protect adults against the serotypes responsible for the majority of invasive pneumococcal disease (IPD) cases.The incidence of invasive pneumococcal disease (IPD) in Spain is approximately 15.08 (95% CI 11.01-20.65) per 100,000 population, compared to 2.56 (95% CI 1.54-4.24) per 100,000 population in Italy.
• According to the insights, the incidence of IPD in 2022-23 was 34% higher in children (under 15 years) compared to 2019-20, while it was 17% lower in adults (15 years and older).
• The annual incidence of IPD in children under 2 years old was 145 cases per 100,000 individuals, while for children under 5 years old and adults over 65 years old, the incidence was 72 and 32 cases per 100,000 individuals, respectively.
• The European Centre for Disease Prevention and Control reports that the incidence of IPD in Europe ranges from 0.4 to 20 cases per 100,000 population. However, due to the varying surveillance strategies for IPD across Europe, comparing data becomes challenging.
• According to the insights, a notably larger proportion of IPD rates has consistently been higher in males than in females across all age groups. The incidence of IPD is especially increased among older male adults, with the highest rates occurring in men aged 65 and older.
• Key Invasive Pneumococcal Disease Companies: MSD K.K, Pfizer, SK Bioscience/ Sanofi, Walvax Biotechnology Co., Ltd., GlaxoSmithKline, and others
• Key Invasive Pneumococcal Disease Therapies: VAXNEUVANCE, PREVENAR 20, GBP-410, Walvax PCV13-TT, Pneumococcal vaccine GSK513026, Pneumovax 23™, and others
• The Invasive Pneumococcal Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Invasive Pneumococcal Disease pipeline products will significantly revolutionize the Invasive Pneumococcal Disease market dynamics.

Invasive Pneumococcal Disease Overview
Invasive pneumococcal disease (IPD) is a severe infection caused by the bacterium Streptococcus pneumoniae. This disease occurs when the bacteria invade normally sterile areas of the body, such as the bloodstream (bacteremia) or the membranes surrounding the brain and spinal cord (meningitis). IPD can lead to serious health complications, including pneumonia, sepsis, and death, particularly in vulnerable populations such as young children, the elderly, and individuals with weakened immune systems. Symptoms may vary depending on the site of infection but often include fever, chills, cough, and difficulty breathing. Vaccination is an effective way to prevent IPD.

Get a Free sample for the Invasive Pneumococcal Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Invasive Pneumococcal Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Invasive Pneumococcal Disease Epidemiology Segmentation:
The Invasive Pneumococcal Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Invasive Pneumococcal Disease
• Prevalent Cases of Invasive Pneumococcal Disease by severity
• Gender-specific Prevalence of Invasive Pneumococcal Disease
• Diagnosed Cases of Episodic and Chronic Invasive Pneumococcal Disease

Download the report to understand which factors are driving Invasive Pneumococcal Disease epidemiology trends @ Invasive Pneumococcal Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/invasive-pneumococcal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Invasive Pneumococcal Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Invasive Pneumococcal Disease market or expected to get launched during the study period. The analysis covers Invasive Pneumococcal Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Invasive Pneumococcal Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Invasive Pneumococcal Disease Therapies and Key Companies
• VAXNEUVANCE: MSD K.K
• PREVENAR 20: Pfizer
• GBP-410: SK Bioscience/ Sanofi
• Walvax PCV13-TT: Walvax Biotechnology Co., Ltd.
• Pneumococcal vaccine GSK513026: GlaxoSmithKline
• Pneumovax 23™:GlaxoSmithKline

Discover more about therapies set to grab major Invasive Pneumococcal Disease market share @ Invasive Pneumococcal Disease Treatment Landscape
https://www.delveinsight.com/sample-request/invasive-pneumococcal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Invasive Pneumococcal Disease Market Drivers
• Increasing Incidence Rates
• Vaccine Development
• Government Initiatives
• Awareness Campaigns
• Aging Population
• Rising Healthcare Expenditure

Invasive Pneumococcal Disease Market Barriers
• High Vaccine Costs
• Limited Awareness
• Vaccine Hesitancy
• Regulatory Hurdles
• Diverse Serotypes
• Geographical Disparities

Scope of the Invasive Pneumococcal Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Invasive Pneumococcal Disease Companies: MSD K.K, Pfizer, SK Bioscience/ Sanofi, Walvax Biotechnology Co., Ltd., GlaxoSmithKline, and others
• Key Invasive Pneumococcal Disease Therapies: VAXNEUVANCE, PREVENAR 20, GBP-410, Walvax PCV13-TT, Pneumococcal vaccine GSK513026, Pneumovax 23™, and others
• Invasive Pneumococcal Disease Therapeutic Assessment: Invasive Pneumococcal Disease current marketed and Invasive Pneumococcal Disease emerging therapies
• Invasive Pneumococcal Disease Market Dynamics: Invasive Pneumococcal Disease market drivers and Invasive Pneumococcal Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Invasive Pneumococcal Disease Unmet Needs, KOL's views, Analyst's views, Invasive Pneumococcal Disease Market Access and Reimbursement

To know more about Invasive Pneumococcal Disease companies working in the treatment market, visit @ Invasive Pneumococcal Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/invasive-pneumococcal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Invasive Pneumococcal Disease Market Report Introduction
2. Executive Summary for Invasive Pneumococcal Disease
3. SWOT analysis of Invasive Pneumococcal Disease
4. Invasive Pneumococcal Disease Patient Share (%) Overview at a Glance
5. Invasive Pneumococcal Disease Market Overview at a Glance
6. Invasive Pneumococcal Disease Disease Background and Overview
7. Invasive Pneumococcal Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Invasive Pneumococcal Disease
9. Invasive Pneumococcal Disease Current Treatment and Medical Practices
10. Invasive Pneumococcal Disease Unmet Needs
11. Invasive Pneumococcal Disease Emerging Therapies
12. Invasive Pneumococcal Disease Market Outlook
13. Country-Wise Invasive Pneumococcal Disease Market Analysis (2020-2034)
14. Invasive Pneumococcal Disease Market Access and Reimbursement of Therapies
15. Invasive Pneumococcal Disease Market Drivers
16. Invasive Pneumococcal Disease Market Barriers
17. Invasive Pneumococcal Disease Appendix
18. Invasive Pneumococcal Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Invasive Pneumococcal Disease Pipeline https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Invasive Pneumococcal Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Invasive Pneumococcal Disease market. A detailed picture of the Invasive Pneumococcal Disease pipeline landscape is provided, which includes the disease overview and Invasive Pneumococcal Disease treatment guidelines.

Invasive Pneumococcal Disease Epidemiology https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Invasive Pneumococcal Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Invasive Pneumococcal Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Trastuzuma Biosimilar
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight's, "Trastuzumab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
DelveInsight's "Undifferentiated Pleomorphic Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Undifferentiated Pleomorphic Sarcoma, historical and forecasted epidemiology as well as the Undifferentiated Pleomorphic Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.